Canaccord analyst Richard Close raised the firm’s price target on AdaptHealth (AHCO) to $14 from $13 and keeps a Buy rating on the shares. The firm said 4Q was a step forward in rebuilding investor confidence for Adapt as results showed revenue upside and 2025 guidance that has revenue and adj-EBITDA ranges bracketing both Canaccord and consensus prior estimates, and a respectable FCF range of $180-$220 million.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: